Roche Holding AGXSWX:ROP +2.09%79 ROA % is 11.19% as of Dec. 2025, which is 15% below its 10-year median of 13.20. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Roche Holding AG ranks better than 89.36% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Roche Holding AG's annualizedNet Income for the quarter that ended in Dec. 2025 was CHF10,940 Mil.
Roche Holding AG's average Total Assets over the quarter that ended in Dec. 2025 was CHF97,734 Mil. Therefore, Roche Holding AG's annualized ROA % for the quarter that ended in Dec. 2025 was 11.19%.
The historical rank and industry rank for Roche Holding AG's ROA % or its related term are showing as below:
XSWX:ROP'
s ROA % Range Over the Past 10 Years
Min: 8.61 Med: 13.2 Max: 16.89
Current: 13
During the past 13 years, Roche Holding AG's highest ROA % was 16.89%. The lowest was 8.61%. And the median was 13.20%.
XSWX:ROP's ROA % is ranked better than 89.36% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs XSWX:ROP: 13.00
Roche Holding AG (XSWX:ROP) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Roche Holding AG ROA % Related Terms
Roche Holding AG ROA % Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Roche Holding AG's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's ROA % distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Roche Holding AG (XSWX:ROP) has a ROA % of 11.19% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Roche Holding AG and its competitors. This is 15% below median its historical median of 13.20. Over the past decade, Roche Holding AG's ROA % has ranged from 8.61 to 16.89. According to the industry distribution chart, Roche Holding AG ranks #107 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Roche Holding AG's ROA % too high?
Roche Holding AG's current ROA % of 11.19% is 15% below median its 10-year median of 13.20. Over the past 10 years, this metric has ranged from a low of 8.61 to a high of 16.89. The Drug Manufacturers industry median ROA % is 2.69. Roche Holding AG's value of 11.19% is 316.8% above this industry median. Based on the distribution chart, Roche Holding AG ranks #107 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #107 out of 1006 companies for ROA %. This places Roche Holding AG in the top 11% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Roche Holding AG's value of 11.19% is 316.8% above this benchmark. Historically, Roche Holding AG's own ROA % has ranged from 8.61 to 16.89 over the past decade. While the company's 10-year median is 13.20 vs. the industry median of 2.69, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current ROA % of 11.19% is 316.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current ROA % is 11.19%, which is 15% below median its own 10-year median of 13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current ROA % is 11.19%, which is 15% below median its 10-year median of 13.20 and 316.8% above the Drug Manufacturers industry median of 2.69. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current ROA % is 11.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
ROA %: 11.19% (15% below median its 10-year median of 13.20)
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
Industry Position: 316.8% above the Drug Manufacturers median (#107 of 1006)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score
Get the complete analysis for XSWX:ROP
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
